Bio-Rad Laboratories, Inc.
BIOHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. With a market capitalization of $9.90B, it sits in mid-cap territory. It operates through two segments, Life Science and Clinical Diagnostics.
Market Cap
$9.90B
Beta
1.07
P/E (TTM)
46.89
P/E (Fwd)
37.96
EPS (TTM)
$7.89
EPS (Fwd)
$9.75
ROE
3.1%
ROA
1.7%
Cash
$1.62B
Total Debt
$1.37B
Free CF
$283.2M
52W Change
10.1%
Annual Financials
Cash vs Debt
Where BIO stands vs its 150-day and 200-day moving averages
As of the September 9, 2026 close, BIO finished 26.92% above its 150-day moving average ($299.50) and 25.72% above its 200-day moving average ($302.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIO overbought or oversold?
At the September 9, 2026 close, BIO's RSI(14) was 70.9, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.62B in cash comfortably exceeding the $1.37B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $283.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 3.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.80B (2022) to $2.58B (2025).
Investors considering Bio-Rad Laboratories, Inc. should weigh the typical risks associated with BIO's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIO.